Detailed representation of antibodies against a blue background

CREDIT: iStock.com/adventtr

Bio X Cell announces new brand identity and expanded capabilities in functional antibodies

The updated brand identity underscores nearly 30 years of scientific leadership and a growing portfolio designed for modern preclinical discovery.
| 2 min read
Written byBio X Cell
Register for free to listen to this article
Listen with Speechify
0:00
2:00

Lebanon, NH — October 8, 2025— Bio X Cell, the global leader of functional antibodies for in vivo and emerging preclinical models, unveils a refreshed brand identity which bridges nearly 30 years of scientific leadership in the functional antibody space with expanding, global capabilities across the pre-clinical research workflow.

Since inception nearly 30 years ago, Bio X Cell has provided functional antibody solutions that empower scientists across cancer, immunology, neuroscience, and infectious disease research areas. Bio X Cell boasts the world’s largest production facility dedicated to manufacturing functional antibodies. With a 2,000L monthly throughput capacity, the newly upgraded Bio X Cell manufacturing facility is designed for flexibility to enable custom sizes and formulations tailored for both in vivo animal studies and in vitro-organoids/organs-on-chip studies. Located in the US with expanded global operations in China and Germany and a network of distribution partners enable rapid delivery of Bio X Cell solutions to researchers across the world.

Bio X Cell’s refreshed look marks the company’s deepened commitment to modern research across biopharma, academia, and biotech. As the only life science solutions provider able to support researchers with 100% PhD level technical support and the only functional antibody company able to claim nearly 30,000 product citations, the refreshed branding, logo, and branded typeface represent the evolution of Bio X Cell’s place alongside scientific advancement from classic in vivo models to advanced platforms such as New Alternative Methods (NAM), organoids, spheroids, and organ-on-a-chip systems.

Evolving in tandem with scientific advancements, Bio X Cell is expanding its catalog to include modern antibody solutions such as bispecifics and ADCs, workflow solutions that allow researchers to bridge high-throughput NAM studies with complex in vivo models and custom services which allow scaling and customization of RUO-grade antibodies from milligrams to grams.

“Building on our heritage as a trusted provider of ultra-pure, functional antibodies, we are expanding our capabilities to meet the needs of cutting-edge research models from advanced NAM platforms and organoids to complex in vivo studies.” Christopher Conway, CEO of Bio X Cell. “Backed by PhD-level expertise, our antibody solutions combine scientific rigor with innovative formulation and scalable capacity, ensuring precise, reproducible, and translatable results. Our growing global operations and distribution network provide faster, more reliable access to these critical tools, helping scientists accelerate discovery worldwide.”

As Bio X Cell enters this new chapter, its refreshed brand identity reflects not just where the company has been, but how the company is embracing expansion, innovation, and global reach while continuing to focus on empowering translational research. Bio X Cell remains the trusted partner for scientists working at the forefront of discovery. From classic in vivo models to next-generation platforms, Bio X Cell delivers antibody solutions that move science forward.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

Here are some related topics that may interest you:

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A network of interconnected human icons overlaid on a world map, representing global collaboration and population-scale data connections.
New collaborative initiatives are bringing pharmaceutical R&D together around large-scale datasets to accelerate therapeutic discovery.
Modeling neurotropic viral infections using human cerebral organoids
Using fetal-stage brain organoids, researchers are uncovering how Zika virus impacts neurodevelopment and contributes to microcephaly. 
Completing the real-time data picture in bioprocess development
Explore approaches to integrating timely protein titer measurements with cell health data to improve bioprocess visibility and decision-making.
Drug Discovery News December 2025 Issue
Latest IssueVolume 21 • Issue 4 • December 2025

December 2025

December 2025 Issue

Explore this issue